Lupin Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

The newly launched drug is bioequivalent to Xarelto 2.5 mg from Janssen Pharmaceuticals, Inc.

Rivaroxaban is indicated for reducing the risk of major cardiovascular events in patients with coronary artery disease (CAD) and major thrombotic vascular events in patients with peripheral artery disease (PAD), including those who have undergone lower extremity revascularization due to symptomatic PAD.

According to IQVIA MAT data for January 2025, rivaroxaban tablets USP, 2.5 mg, had estimated annual sales of $446 million in the US.

Mumbai-based Lupin is an innovation-led, transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Lupin’s consolidated net profit jumped 38.81% to Rs 858.86 crore on a 10.60% increase in sales to Rs 5,618.6 crore in Q3 FY25 compared to Q3 FY24.

Shares of Lupin rose 0.69% to Rs 2,043 on the BSE.

Powered by Capital Market - Live News

Lupin has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the U.S. FDA.

Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals, Inc., and indicated:

• to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD)

• to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD.

Rivaroxaban Tablets USP, 2.5 mg (RLD Xarelto®) had estimated annual sales of USD 446 million in the U.S. (IQVIA MAT January 2025).

Powered by Capital Market - Live News

Lupin Ltd gained for a fifth straight session today. The stock is quoting at Rs 2022, up 0.59% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.49% on the day, quoting at 22447.2. The Sensex is at 74002.94, up 0.37%. Lupin Ltd has slipped around 8.14% in last one month.

Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has slipped around 7.63% in last one month and is currently quoting at 20126.8, up 1.33% on the day. The volume in the stock stood at 2.87 lakh shares today, compared to the daily average of 11.26 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 2032.95, up 0.6% on the day. Lupin Ltd is up 21.1% in last one year as compared to a 0.21% drop in NIFTY and a 6.25% drop in the Nifty Pharma index.

The PE of the stock is 29.33 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Lupin has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the U.S. FDA.

Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals, Inc., and indicated:

• to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD)

• to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD.

Rivaroxaban Tablets USP, 2.5 mg (RLD Xarelto®) had estimated annual sales of USD 446 million in the U.S. (IQVIA MAT January 2025).

Powered by Capital Market - Live News

Lupin Ltd gained for a fifth straight session today. The stock is quoting at Rs 2022, up 0.59% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.49% on the day, quoting at 22447.2. The Sensex is at 74002.94, up 0.37%. Lupin Ltd has slipped around 8.14% in last one month.

Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has slipped around 7.63% in last one month and is currently quoting at 20126.8, up 1.33% on the day. The volume in the stock stood at 2.87 lakh shares today, compared to the daily average of 11.26 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 2032.95, up 0.6% on the day. Lupin Ltd is up 21.1% in last one year as compared to a 0.21% drop in NIFTY and a 6.25% drop in the Nifty Pharma index.

The PE of the stock is 29.33 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Lupin has allotted 59,940 equity shares under ESOP on 27 February 2025. In view of the above, the issued and paid-up share capital of the Company has increased to Rs 91,30,81,888 consisting of 45,65,40,944 equity shares of Rs 2/- each.

Powered by Capital Market - Live News

The newly launched drug is bioequivalent to Xarelto 2.5 mg from Janssen Pharmaceuticals, Inc.

Rivaroxaban is indicated for reducing the risk of major cardiovascular events in patients with coronary artery disease (CAD) and major thrombotic vascular events in patients with peripheral artery disease (PAD), including those who have undergone lower extremity revascularization due to symptomatic PAD.

According to IQVIA MAT data for January 2025, rivaroxaban tablets USP, 2.5 mg, had estimated annual sales of $446 million in the US.

Mumbai-based Lupin is an innovation-led, transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Lupin’s consolidated net profit jumped 38.81% to Rs 858.86 crore on a 10.60% increase in sales to Rs 5,618.6 crore in Q3 FY25 compared to Q3 FY24.

Shares of Lupin rose 0.69% to Rs 2,043 on the BSE.

Powered by Capital Market - Live News

Lupin has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the U.S. FDA.

Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals, Inc., and indicated:

• to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD)

• to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD.

Rivaroxaban Tablets USP, 2.5 mg (RLD Xarelto®) had estimated annual sales of USD 446 million in the U.S. (IQVIA MAT January 2025).

Powered by Capital Market - Live News

Lupin Ltd gained for a fifth straight session today. The stock is quoting at Rs 2022, up 0.59% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.49% on the day, quoting at 22447.2. The Sensex is at 74002.94, up 0.37%. Lupin Ltd has slipped around 8.14% in last one month.

Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has slipped around 7.63% in last one month and is currently quoting at 20126.8, up 1.33% on the day. The volume in the stock stood at 2.87 lakh shares today, compared to the daily average of 11.26 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 2032.95, up 0.6% on the day. Lupin Ltd is up 21.1% in last one year as compared to a 0.21% drop in NIFTY and a 6.25% drop in the Nifty Pharma index.

The PE of the stock is 29.33 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Lupin has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the U.S. FDA.

Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals, Inc., and indicated:

• to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD)

• to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD.

Rivaroxaban Tablets USP, 2.5 mg (RLD Xarelto®) had estimated annual sales of USD 446 million in the U.S. (IQVIA MAT January 2025).

Powered by Capital Market - Live News

Lupin Ltd gained for a fifth straight session today. The stock is quoting at Rs 2022, up 0.59% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.49% on the day, quoting at 22447.2. The Sensex is at 74002.94, up 0.37%. Lupin Ltd has slipped around 8.14% in last one month.

Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has slipped around 7.63% in last one month and is currently quoting at 20126.8, up 1.33% on the day. The volume in the stock stood at 2.87 lakh shares today, compared to the daily average of 11.26 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 2032.95, up 0.6% on the day. Lupin Ltd is up 21.1% in last one year as compared to a 0.21% drop in NIFTY and a 6.25% drop in the Nifty Pharma index.

The PE of the stock is 29.33 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Lupin has allotted 59,940 equity shares under ESOP on 27 February 2025. In view of the above, the issued and paid-up share capital of the Company has increased to Rs 91,30,81,888 consisting of 45,65,40,944 equity shares of Rs 2/- each.

Powered by Capital Market - Live News